Carregant...
Potential for Long‐Term Disease Control with Alpelisib Plus Fulvestrant Spans Patient Subgroups in HR+ PIK3CA‐Mutated Advanced Breast Cancer
Alpelisib plus fulvestrant provides long‐term disease control in patients with endocrine‐resistant, HR‐positive, HER2‐negative, PIK3CA‐mutated advanced breast cancer, according to an updated analysis from the SOLAR‐1 and X2101 trials.
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8262312/ https://ncbi.nlm.nih.gov/pubmed/34173298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13873 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|